Biotech Values

[alertmeipp]

>>Think of the decision as if your job depended on it - if you licensed it after NVS passed and it eventually failed in phase 2 trials. Everyone would have pointed to the NVS as a red flag that the drug didnt work and you'd be out on the street.

If it's my job, the fact the NVS pass will be one of the inputs I will consider - but won't be an important one.

NVS owns ~50% of IDIX already, they will participate the potential of the drug either directly or indirectly anyways.

Maybe NVS is buying the whole thing - why partner...;)